Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Redmile Group, LLC and related entities report significant ownership in Nurix Therapeutics, Inc. Redmile Group, LLC and its principal, Jeremy C. Green, each report beneficial ownership of 8,782,256 shares of Nurix common stock, representing 8.1% of the class. This stake consists of 4,073,787 outstanding shares and 4,708,469 shares issuable upon exercise of pre-funded warrants held by investment vehicles managed by Redmile. RedCo II Offshore SPV LLC, one such vehicle, reports beneficial ownership of 3,712,546 shares, or 3.5%, including shares issuable upon warrant exercise. Beneficial ownership percentages are based on 103,781,683 shares outstanding as of June 30, 2026, plus the relevant warrant shares. Voting and dispositive powers are reported as shared, with Redmile and Mr. Green disclaiming beneficial ownership beyond their pecuniary interest.
Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of Nurix Therapeutics, Inc. common stock on an amended Schedule 13G. They report beneficial ownership of 8,050,000 shares of common stock, representing 7.8% of the class, based on 103,781,683 shares outstanding as of June 30, 2026. The shares are held by a Vestal Point fund and a managed account, over which the reporting persons have shared voting and dispositive power and no sole power. The filing states it should not be construed as an admission that any reporting person is a beneficial owner for Section 13 purposes.
Rubric Capital Management LP and David Rosen reported beneficial ownership of Nurix Therapeutics, Inc. common stock. They collectively hold 7,227,778 shares of common stock, representing 6.96% of the class. The ownership is held through Rubric Capital–managed funds, including Rubric Capital Master Fund LP, which has rights to receive dividends and sale proceeds on more than 5% of the shares.
The percentage ownership is based on 103,781,683 shares outstanding of Nurix common stock as of June 30, 2026, as referenced from the company’s quarterly report. All reported voting and dispositive powers are shared, with no sole voting or dispositive power reported by the filing parties.
T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Nurix Therapeutics, Inc. (NRIX). The firm reported holding 5,436,587 shares of common stock, representing 5.3% of the outstanding class. It reported sole voting power over 5,250,628 shares and sole dispositive power over 5,436,587 shares, with no shared voting or dispositive power. T. Rowe Price Associates stated that this filing should not be construed as an admission that it is the beneficial owner of these securities and expressly denied such beneficial ownership.
Nurix Therapeutics, Inc. has a significant shareholder group led by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, which jointly report beneficial ownership of 7,736,455 shares of common stock. This represents 7.45% of Nurix’s common stock outstanding as of June 30, 2026, based on 103,781,683 shares reported in the company’s 10-Q. The reporting persons hold no sole voting or dispositive power but have shared voting and shared dispositive power over all 7,736,455 shares, indicating coordinated control over how this block may be voted or sold.
Nurix Therapeutics, Inc. reported that Chief Scientific Officer Gwenn Hansen exercised employee stock options for 4,356 shares at an exercise price of $1.8600 per share and sold 4,356 common shares at $25.0000 per share on August 5, 2026 under a Rule 10b5-1 trading plan. After the exercise, 62,310 options from this grant remained outstanding, with an option expiration date of 2029-08-28.
A shareholder of NRIX, identified as Gwenn M. Hansen, filed to sell common stock, including 8,712 shares through Morgan Stanley Smith Barney LLC Executive Financial Services, tied to an exercise of stock options on 08/05/2026. The filing also lists several recent Rule 10b5-1 plan sales of common shares over the prior three months.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported selling a total of 4,111 shares of common stock on 2026-08-04 in two transactions at weighted average prices of $23.8684 and $24.6415. The sales were effected pursuant to a previously adopted Rule 10b5-1 trading plan.
Nurix Therapeutics, Inc. reported that Chief Financial Officer Hans van Houte sold a total of 4,761 shares of common stock on August 4, 2026, in two open-market or private transactions at weighted average prices of $23.8911 and $24.6474 per share pursuant to a previously adopted Rule 10b5-1 trading plan, with sale prices ranging between $23.42 and $24.83.
NRIX received a notice of proposed stock sales by an affiliate. The filing lists plans to sell 4,111 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, associated with restricted stock units dated July 30, 2026, on NASDAQ. It also notes prior Rule 10b5-1 sales for Gwenn M. Hansen totaling 5,394 common shares on June 25, 2026 for $107,880.00.